Physician profile
Alec Platt
NPI 1871656363
$7,834.47
in general payments reported to CMS, 2019-2025
40 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $1,235 · 2021: $802 · 2022: $248 · 2023: $1,179 · 2024: $1,594 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,017.29 |
| Education | $117.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,612.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $645.74 | 2019-2024 | Tezspire, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $628.24 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $615.99 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $403.47 | 2019-2025 | Dupixent |
| Genzyme Corporation | $376.64 | 2019-2025 | |
| Mylan Specialty L.P. | $259.30 | 2019-2024 | Yupelri |
| Insmed, INC. | $251.99 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $246.80 | 2019-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $220.68 | 2023-2025 | Lumryz |
| Janssen Pharmaceuticals, INC | $219.91 | 2019-2021 | |
| Grifols USA, LLC | $183.18 | 2019-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $163.78 | 2019-2025 | Zerbaxa, Recarbrio, Winrevair |
| Verona Pharma, INC. | $140.90 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $133.22 | 2020-2025 | Glassia |
| Pulmonx Corporation | $130.05 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Axsome Therapeutics, INC. | $117.08 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $115.02 | 2019-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $108.61 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $93.35 | 2019-2022 | |
| Genentech USA, INC. | $89.27 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $70.09 | 2021-2024 | Opsumit, Uptravi |
| Vifor Pharma, INC. | $65.50 | 2024-2025 | Zemaira, Veltassa |
| Inspire Medical Systems, INC. | $62.01 | 2023-2025 | Inspire |
| Electromed, INC. | $58.37 | 2019-2021 | |
| Astellas Pharma US INC | $46.51 | 2019-2021 | |
| Advanced Respiratory, INC | $46.25 | 2019-2020 | |
| Shire North American Group INC | $38.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.34 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.91 | 2023 | Ultomiris |
| 3b Medical, INC. | $24.54 | 2025 | Luna |
| Sunovion Pharmaceuticals INC. | $21.63 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.66 | 2024 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $18.63 | 2024 | Nuzyra |
| Lilly USA, LLC | $14.75 | 2025 | Zepbound |
| Viatris Specialty LLC | $14.42 | 2025 | Yupelri |
| Portola Pharmaceuticals, LLC | $12.36 | 2020 | |
| Pfizer INC. | $12.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Platt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.